Published in Cancer Treat Rep on February 01, 1985
Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ (2000) 5.43
The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA (1995) 5.05
The Internet and evidence-based decision-making: a needed synergy for efficient knowledge management in health care. CMAJ (2000) 3.46
A guide to interpreting discordant systematic reviews. CMAJ (1997) 2.29
Serologic diagnosis of disseminated candidiasis in patients with acute leukemia. Ann Intern Med (1969) 2.28
Hemoglobin biosynthesis in murine virus-induced leukemic cells in vitro: structure and amounts of globin chains produced. Blood (1972) 1.81
Hemoglobin synthesis in murine virus-induced leukemic cells in vitro. 3. Effects of 5-bromo-2'-deoxyuridine, dimethylformamide and dimethylsulfoxide. J Cell Physiol (1973) 1.78
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res (2000) 1.66
Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation. Nature (1976) 1.59
Simple atrophic gastritis and gastric carcinoma. Gut (1971) 1.46
Cryoprotective agents as inducers of erythroleukemic cell differentiation in vitro. Blood (1976) 1.42
Systemic adjuvant therapy for node-negative breast cancer. CMAJ (1989) 1.42
Science, language, intuition, and the many meanings of quality of life. J Clin Oncol (1999) 1.42
Scientific evidence and expert opinion in ACP Journal Club: commentary on commentaries. ACP J Club (1994) 1.40
Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf (2011) 1.39
Gastrointestinal "sterilization" in the treatment of patients with acute leukemia. Cancer (1970) 1.39
Assessment of cell-cycle effects of cytokines in vivo. J Clin Oncol (1992) 1.38
Studies on the control of differentiation of murine virus-induced erythroleukemic cells. Curr Top Dev Biol (1974) 1.35
Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986. Cancer (1989) 1.33
Differentiation of erythroleukemia cells in vitro: properties of chemical inducers. Cell Differ (1975) 1.32
The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukemia. Blood (1986) 1.26
A controlled "before-after" study: impact of a clinical guidelines programme and regional cancer network organization on medical practice. Br J Cancer (2002) 1.24
When is a prognostic factor useful? A guide for the perplexed. J Clin Oncol (1991) 1.20
Development and aftercare of clinical guidelines: the balance between rigor and pragmatism. JAMA (2001) 1.16
c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res (1992) 1.13
Lymphoma with hypercalcemia. Can Med Assoc J (1974) 1.12
Anti-Candida antibodies in patients with acute leukemia. A prospective study. Am J Med (1971) 1.11
Murine myeloid leukemia: I. Pathophysiology and drug sensitivity. Cancer Treat Rep (1977) 1.10
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood (1979) 1.03
Differentiation of erythroleukemic cells in vitro: irreversible induction by dimethyl sulfoxide (DMSO). J Cell Physiol (1975) 1.02
The CD34 hemopoietic progenitor cell associated antigen: biology and clinical applications. Haematologica (1992) 1.02
Fermi-liquid breakdown in the paramagnetic phase of a pure metal. Nature (2003) 1.02
Funding new cancer drugs in Ontario: closing the loop in the practice guidelines development cycle. J Clin Oncol (2001) 0.98
Phospholipid membrane stabilization by dimethylsulfoxide and other inducers of Friend leukemic cell differentiation. Biochim Biophys Acta (1976) 0.97
Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemia. Blood (1985) 0.96
Hemoglobin abnormalities in neoplastic hematological disorders. Can Med Assoc J (1973) 0.96
Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and response to therapy. Cancer Res (1979) 0.96
Loss of factor VIII activity during storage in PVC containers due to adsorption. Haemophilia (2000) 0.95
Thrombocytopenia in septicemia: the role of disseminated intravascular coagulation. Blood (1980) 0.94
Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplant (2000) 0.94
Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res (1997) 0.94
Early detection of HIV infection in a newborn. N Engl J Med (1987) 0.93
Searching the medical literature for the best evidence to solve clinical questions. Ann Oncol (1998) 0.92
CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. Am J Hematol (2001) 0.92
Orthotopic liver transplantation in a patient with combined hemophilia A and B. Am J Hematol (1990) 0.92
Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase. Leuk Res (1997) 0.92
Two in situ labeling techniques reveal different patterns of DNA fragmentation during spontaneous apoptosis in vivo and induced apoptosis in vitro. Anticancer Res (1996) 0.90
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol (1987) 0.88
Differences in cell cycle characteristics among patients with acute nonlymphocytic leukemia. Blood (1987) 0.88
Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther (2000) 0.87
Alteration of binding of the supravital dye Hoechst 33342 to human leukemic cells by adriamycin. Cancer Treat Rep (1978) 0.87
Immunoperoxidase detection of myeloid antigens in glycolmethacrylate-embedded human bone marrow. J Histochem Cytochem (1987) 0.86
SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine (2000) 0.86
Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res (1990) 0.86
Double labeling and in vitro versus in vivo incorporation of bromodeoxyuridine in patients with acute nonlymphocytic leukemia. Cytometry (1985) 0.86
A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res (1982) 0.85
Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynx. Auris Nasus Larynx (2002) 0.85
Loss of clonogenicity in agar by differentiating erythroleukemic cells. Life Sci (1975) 0.85
Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia. Haemophilia (2007) 0.85
Double labeling of human leukemic cells using 3H-cytarabine and monoclonal antibody against bromodeoxyuridine. Cancer Treat Rep (1985) 0.85
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol (1984) 0.85
Cytokine gene activity in AML cells in vivo in patients. Leuk Res (1998) 0.85
Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia. Br J Haematol (1984) 0.85
Prediction of response to chemotherapy in acute myelocytic leukemia. Blood (1980) 0.85
Resistance to photodynamic therapy in radiation induced fibrosarcoma-1 and Chinese hamster ovary-multi-drug resistant. Cells in vitro. Photochem Photobiol (1991) 0.84
Adriamycin-cytosine arabinoside therapy for adult acute myelocytic leukemia. Cancer Treat Rep (1977) 0.84
Rapid enumeration of S-phase cells by means of monoclonal antibodies. N Engl J Med (1984) 0.84
Health care professionals' familiarity with non-pharmacological strategies for managing cancer pain. Psychooncology (1999) 0.83
Comparison between agar and methylcellulose cultures of human leukemic cells. Cancer Res (1981) 0.83
Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study. Br J Haematol (1989) 0.83
Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. Int J Radiat Oncol Biol Phys (2001) 0.83
Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: a leukemia intergroup study. Blood (1990) 0.83
Accuracy of histone H3 messenger RNA in situ hybridization for the assessment of cell proliferation in human tissues. Clin Cancer Res (1997) 0.83
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation. Cancer Res (1977) 0.83
Effects of partially thiolated polycytidylic acid on the clonogenicity of murine leukemic stem cells. Cancer Res (1979) 0.82
The treatment of acute myelocytic leukemia in patients 30 years of age and younger. Am J Hematol (1982) 0.82
The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. Br J Cancer (1992) 0.82
Expression of the protooncogenes c-myc, c-fos, and c-fms in acute myelocytic leukemia at diagnosis and in remission. Cancer Res (1987) 0.82
Alcian blue method for attaching glycol methacrylate bone marrow sections to glass slides. Stain Technol (1986) 0.82
Acute nonlymphocytic leukemia in a glue sniffer. Am J Hematol (1985) 0.82
Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant (1993) 0.81
Cell kinetics of head and neck cancers. Clin Cancer Res (1995) 0.81
Inducers of Friend leukaemic cell differentiation in vitro--effects of in vivo administration. Br J Cancer (1976) 0.81
Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute non-lymphocytic leukemia. Eur J Cancer Clin Oncol (1985) 0.81
Evaluation of c-myc proto-oncogene in primary human breast carcinomas. Anticancer Res (1992) 0.81
Chronic eosinophilic leukemia presenting with autoimmune hemolytic anemia and erythrophagocytosis by eosinophils. Am J Hematol (2006) 0.81
Studies on erythroid differentiation of Friend virus-induced murine leukemic cells. Bibl Haematol (1973) 0.81
Erythroid colony formation in vitro by dimethylsulfoxide-treated erythroleukemic cells. Blood (1974) 0.81
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements. Br J Haematol (1986) 0.80
Regulators of proliferation and apoptosis in carcinoma of the larynx. Laryngoscope (1998) 0.80
Utility and sensitivity of anti BrdU antibodies in assessing S-phase cells compared to autoradiography. Cell Biochem Funct (1985) 0.80
Factors XI and XII are low in subjects with liver disease. Dig Dis Sci (1983) 0.80
Immunohistochemical detection of c-myc oncoprotein in paraffin embedded tissues. J Exp Pathol (1990) 0.80
Uptake of adriamycin by human leukemic cells as measured by flow cytometry. Med Oncol Tumor Pharmacother (1984) 0.80
The effects of 13-cis retinoic acid and interferon-alpha in chronic myelogenous leukemia cells in vivo in patients. Leuk Res (1998) 0.80
The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol (1999) 0.79